Evaluation of bevacizumab, pegaptanib and ranibizumab for intraocular neovasculalization and/or macular edema

Evaluation of bevacizumab, pegaptanib and ranibizumab for intraocular neovasculalization and/or macular edema - Evaluation of bevacizumab, pegaptanib and ranibizumab for intraocular neovasculalization and/or macular edema

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006992

Enrollment

Registered

2011-12-30

Start date

2011-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic retinopathy, branch retinal vein occlusion, central retinal vein occlusion, choroidal neovasucularization, neovascular maculopathy

Interventions

Intravitreal bevacizumab for treatment Intravitreal pegaptanib for treatment Intravitreal ranibizumab for treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Outpatients of Shiga University of Medical Science with intraocular neovasculalization or macular edema that are examined by angiography or checked retinal thickness.

Exclusion criteria

Exclusion criteria: severe glaucoma unstable angina malignant arrhythmia anaphylaxis

Design outcomes

Primary

Measure	Time frame
Variation on a logarithm of the minimum angle of resolution 12 months after the first intravitreal injection	—

Secondary

Measure	Time frame
The rate of complication 12 months after the first intravitreal injection Variation on a central retinal thickness	—

Countries

Japan

Contacts

Public ContactYoshitsugu Saishin

Shiga University of Medical Science Department of Ophthalmology

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026